CY1107841T1 - Φαρμακευτικα σκευασματα τα οποια περιλαμβανουν μυκοφαινολικο οξυ ή μυκοφαινολικο αλας - Google Patents

Φαρμακευτικα σκευασματα τα οποια περιλαμβανουν μυκοφαινολικο οξυ ή μυκοφαινολικο αλας

Info

Publication number
CY1107841T1
CY1107841T1 CY20071101618T CY071101618T CY1107841T1 CY 1107841 T1 CY1107841 T1 CY 1107841T1 CY 20071101618 T CY20071101618 T CY 20071101618T CY 071101618 T CY071101618 T CY 071101618T CY 1107841 T1 CY1107841 T1 CY 1107841T1
Authority
CY
Cyprus
Prior art keywords
mycophenolic acid
mycophenolate salt
containing mycophenolic
particulars
pharmaceutical
Prior art date
Application number
CY20071101618T
Other languages
Greek (el)
English (en)
Inventor
Jürgen Dederichs
Thomas Rigassi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107841(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1107841T1 publication Critical patent/CY1107841T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
CY20071101618T 2001-10-17 2007-12-19 Φαρμακευτικα σκευασματα τα οποια περιλαμβανουν μυκοφαινολικο οξυ ή μυκοφαινολικο αλας CY1107841T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124953.1A GB0124953D0 (en) 2001-10-17 2001-10-17 Organic Compounds
EP02777314.2A EP1438040B2 (en) 2001-10-17 2002-10-16 Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt

Publications (1)

Publication Number Publication Date
CY1107841T1 true CY1107841T1 (el) 2013-06-19

Family

ID=9924043

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101618T CY1107841T1 (el) 2001-10-17 2007-12-19 Φαρμακευτικα σκευασματα τα οποια περιλαμβανουν μυκοφαινολικο οξυ ή μυκοφαινολικο αλας

Country Status (31)

Country Link
US (3) US20050013859A1 (cg-RX-API-DMAC7.html)
EP (1) EP1438040B2 (cg-RX-API-DMAC7.html)
JP (2) JP2005508959A (cg-RX-API-DMAC7.html)
KR (1) KR100671367B1 (cg-RX-API-DMAC7.html)
CN (1) CN1310640C (cg-RX-API-DMAC7.html)
AR (2) AR036813A1 (cg-RX-API-DMAC7.html)
AT (1) ATE374023T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002338897B2 (cg-RX-API-DMAC7.html)
BR (1) BR0213355A (cg-RX-API-DMAC7.html)
CA (1) CA2460574A1 (cg-RX-API-DMAC7.html)
CO (1) CO5390076A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107841T1 (cg-RX-API-DMAC7.html)
DE (1) DE60222687T3 (cg-RX-API-DMAC7.html)
DK (1) DK1438040T4 (cg-RX-API-DMAC7.html)
EC (2) ECSP024341A (cg-RX-API-DMAC7.html)
ES (1) ES2292819T5 (cg-RX-API-DMAC7.html)
GB (1) GB0124953D0 (cg-RX-API-DMAC7.html)
HU (1) HU231114B1 (cg-RX-API-DMAC7.html)
IL (2) IL160968A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04003636A (cg-RX-API-DMAC7.html)
MY (1) MY139206A (cg-RX-API-DMAC7.html)
NO (1) NO341804B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ532280A (cg-RX-API-DMAC7.html)
PE (1) PE20030476A1 (cg-RX-API-DMAC7.html)
PL (2) PL234541B1 (cg-RX-API-DMAC7.html)
PT (1) PT1438040E (cg-RX-API-DMAC7.html)
RU (2) RU2338528C2 (cg-RX-API-DMAC7.html)
SI (1) SI1438040T2 (cg-RX-API-DMAC7.html)
TW (1) TWI333861B (cg-RX-API-DMAC7.html)
WO (1) WO2003032978A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200401977B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
WO2006012379A2 (en) * 2004-07-20 2006-02-02 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Processes for preparation of crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
WO2006086498A2 (en) 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
BRPI0616640A2 (pt) * 2005-09-30 2011-06-28 Novartis Ag combinação de compostos orgánicos
EP1965760B1 (de) 2005-12-21 2013-02-27 Basf Se Feinteiliges quervernetztes polyvinylpyrrolidon als tablettensprengmittel
CN101378749A (zh) * 2006-02-13 2009-03-04 诺瓦提斯公司 高剂量的麦考酚酸(mpa)
US10406105B2 (en) 2007-06-06 2019-09-10 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
US8568780B2 (en) 2007-06-06 2013-10-29 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
AU2008288106B2 (en) * 2007-08-13 2012-03-15 Panacea Biotec Limited Extended release compositions comprising mycophenolate sodium and processes thereof
JP2011513391A (ja) * 2008-03-05 2011-04-28 パナセア バイオテック リミテッド ミコフェノラートを含有する徐放性医薬組成物およびその方法
CA2729834A1 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102793658A (zh) * 2012-08-23 2012-11-28 无锡福祈制药有限公司 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片
CN103845323B (zh) * 2012-11-30 2018-02-02 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
CN106727403A (zh) * 2017-01-03 2017-05-31 无锡福祈制药有限公司 一种麦考酚钠肠溶片及其制备方法
US11633378B2 (en) * 2017-03-13 2023-04-25 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
SG11202007172YA (en) 2018-06-06 2020-08-28 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
JP7266616B2 (ja) * 2018-06-14 2023-04-28 ポクセル 糖尿病の治療において使用するためのトリアジン誘導体を含むフィルムコーティング錠剤
RU2723255C2 (ru) * 2018-11-14 2020-06-09 Общество с ограниченной ответственностью "Изварино Фарма" Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
MX2023008907A (es) * 2021-01-28 2023-08-09 Priothera Sas Metodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p).
US20240261218A1 (en) * 2021-05-26 2024-08-08 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN117442580B (zh) * 2023-12-21 2024-04-05 泊诺(天津)创新医药研究有限公司 一种高生物利用度麦考酚钠肠溶片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) † 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
JPS56127093A (en) * 1980-03-10 1981-10-05 Ajinomoto Co Inc Preparation of mycophenolic acid
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
US4748173A (en) * 1987-01-30 1988-05-31 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
AU3178293A (en) * 1992-11-24 1994-06-22 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
CZ286051B6 (cs) * 1993-02-26 1999-12-15 The Procter & Gamble Company Farmaceutický prostředek a způsob jeho použití pro dasažení projímavého účinku
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
HU228672B1 (en) * 1993-10-01 2013-05-28 Syntex Inc Mycophenolate mofetil high dose oral suspensions and process for preparing them
WO1995011024A1 (en) * 1993-10-19 1995-04-27 The Procter & Gamble Company Picosulphate dosage form
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
DE60044717D1 (de) * 1999-05-10 2010-09-02 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
HUP9903226A2 (en) * 1999-09-23 2002-08-28 Gyogyszerki Process for producing mycophenolic acid and derivatives thereof
CZ20022913A3 (cs) * 2000-02-29 2003-02-12 Biocon India Limited Výroba a čištění kyseliny mykofenolové
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20100210717A1 (en) 2010-08-19
EP1438040B1 (en) 2007-09-26
PL367738A1 (en) 2005-03-07
US20050013859A1 (en) 2005-01-20
HUP0600451A2 (en) 2006-09-28
MY139206A (en) 2009-08-28
RU2381026C2 (ru) 2010-02-10
NO20041785L (no) 2004-05-03
RU2004115332A (ru) 2005-04-20
PL234541B1 (pl) 2020-03-31
AU2002338897B2 (en) 2006-10-19
HK1067861A1 (en) 2005-04-22
AR036813A1 (es) 2004-10-06
DE60222687D1 (de) 2007-11-08
ATE374023T1 (de) 2007-10-15
NZ532280A (en) 2007-05-31
ZA200401977B (en) 2006-05-31
CN1310640C (zh) 2007-04-18
PL415001A1 (pl) 2016-02-29
WO2003032978A1 (en) 2003-04-24
CN1564684A (zh) 2005-01-12
RU2007130786A (ru) 2009-02-20
ES2292819T5 (es) 2020-05-29
JP2005508959A (ja) 2005-04-07
DE60222687T3 (de) 2020-03-05
IL160968A (en) 2016-04-21
MXPA04003636A (es) 2004-07-27
KR100671367B1 (ko) 2007-01-19
JP2009137996A (ja) 2009-06-25
AR085778A2 (es) 2013-10-30
SI1438040T2 (sl) 2020-02-28
RU2338528C2 (ru) 2008-11-20
DE60222687T2 (de) 2008-07-17
CO5390076A1 (es) 2004-04-30
SI1438040T1 (sl) 2008-04-30
HU231114B1 (hu) 2020-09-28
PT1438040E (pt) 2008-01-02
PE20030476A1 (es) 2003-07-30
US20120237601A1 (en) 2012-09-20
DK1438040T4 (da) 2020-01-27
ECSP024341A (es) 2003-12-01
ES2292819T3 (es) 2008-03-16
EP1438040B2 (en) 2019-10-16
GB0124953D0 (en) 2001-12-05
ECSP024342A (es) 2003-03-10
BR0213355A (pt) 2006-05-23
DK1438040T3 (da) 2008-02-04
CA2460574A1 (en) 2003-04-24
EP1438040A1 (en) 2004-07-21
NO341804B1 (no) 2018-01-22
TWI333861B (en) 2010-12-01
KR20050037409A (ko) 2005-04-21
IL160968A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
CY1107841T1 (el) Φαρμακευτικα σκευασματα τα οποια περιλαμβανουν μυκοφαινολικο οξυ ή μυκοφαινολικο αλας
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
DK1036058T3 (da) Adamantanderivater
DE69808130D1 (de) Adamantan-derivate
NL1015859A1 (nl) Farmaceutische preparaten.
ATE553780T1 (de) Ph-sensitives polymer
CY1106919T1 (el) Μεθοδος για τη βελτιωση της σταθεροτητας μιας φαρμακευτικης συνθεσης
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
ATE291908T1 (de) Ibuprofen-wirkstoffzubereitung
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
EA200400455A1 (ru) Способ приготовления быстрорастворимой дозировочной формы
CY1105465T1 (el) Μορφη δοσολογιας πepιλαμβανουσα υγρο σκευασμα
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
CY1109496T1 (el) Τρυγικο και φωσφορικο αλας της 3,4-διαμινοπυριδινης, φαρμακευτικες συνθεσεις και χρησεις αυτων
DE60134414D1 (de) 4-pyrimidinamine derivate, pharmazeutische zusammenstellungen und verwandte methoden
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda